News Novartis takes aim at Shire and Allergan with dry-eye drug Swiss company takes option on Lubris' ECF843.
News Shire launches potential blockbuster dry eye drug in US Xiidra could be ophthalmology blockbuster.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
